ArticleMedicine2025
Systematic analysis of adverse reactions associated with dantrolene treatment: From clinical features to molecular mechanisms.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dantrolene, 1st synthesized in 1967, is widely used for treating malignant hyperthermia (MH), neuroleptic malignant syndrome, and spasticity. However, comprehensive analysis of its adverse effects and underlying mechanisms remains limited. This study aims to analyze dantrolene-associated adverse events (AEs) using pharmacovigilance databases, with particular focus on subgroup analysis comparing MH versus non-MH patients, and investigate their underlying molecular mechanisms. We analyzed AEs from 3 pharmacovigilance databases (U.S. Food and Drug Administration Adverse Event Reporting System [2004-2024], Japanese Adverse Drug Event Report [2004-2023], Canada Vigilance Adverse Reaction Online Database [1991-2019]) and conducted differential gene expression analysis using GEO datasets (GSE184769, GSE227229). Signal detection employed disproportionality analysis using reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and Empirical Bayesian Geometric Mean indices. Analysis revealed significant respiratory and musculoskeletal AEs. Respiratory failure was consistently reported across databases (ROR: 29.33-46.29), while musculoskeletal complications included rhabdomyolysis (ROR: 14.05) and compartment syndrome (ROR: 80.52). MH patients showed increased risks of muscular weakness (ROR: 19.00), respiratory failure (ROR: 5.48), and pulmonary edema (ROR: 22.18). Molecular analysis identified IL6 and ALB as key mediators of respiratory effects, while Adgrl1 and Adgrl2 emerged as crucial regulators of muscle function. Our study quantified differential dantrolene susceptibility, revealing significantly higher AE risks in MH versus non-MH patients: muscular weakness (ROR: 19.00), respiratory failure (ROR: 5.48), and pulmonary edema (ROR: 22.18). Molecular analysis demonstrated that mutant ryanodine receptor 1 channels amplify IL6/ALB-mediated respiratory effects and disrupt Adgrl1/2-regulated muscle function, establishing the mechanistic basis for MH patient vulnerability and supporting MH-specific dosing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.